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ABSTRACT
A series of experiments were undertaken to observe the effects of
prostaglandin F2~ (PGF 2o1,

),

acetylsalicylic acid (aspirin), follicle

stimulating hormone (FSH) and luteinizing hormone (IH) on estrogen biosynthesis in the ovary as revealed histochemically; also pursued were
the histologic morphology of the ovary, and the gravimetric changes of
the ovaries, adrenal glands and body weights of immature, female rats
when given the aforementioned during the period of developing reproductive
competency.
Five major groups of thirty 22 day old female rats (one control group
and four treatment groups) were given subcutaneous injections, twice daily,
of either 75 micrograms of PGF 2o<. , five milligrams of aspirin, 0.25 Armour
Unit

of FSH or 0.125 Armour Standard Unit

of I.H.

Sub-groups of ten rats

in each major treatment category were necropsied at 27, 33 or 37 days of
age.

Body weights, ovarian weights and adrenal gland weights were re-

corded and statistically analyzed.

Ovarian sections were prepared for

histologic morphology, and for histochemical
epiandrosterone-3~-hydroxysteroid

analysis,~-~··

dehydrogenase (DHA-3¥-HSD) activity,

which is indicative of the precursors of estrone and
synthesis in the ovary.

dehydro-

estradiol-17~

bio-

DHA-3p-HSD activity in the ovary, and adrenal

gland weights were used as indices of the metabolic activity in these endocrine organs.

The results indicated that systemic administration of PGF 2o( or
aspirin in the immature female rat caused a significant increase of
steroidogenesis in the ovary and the adrenal gland, and that this steroidogenic effect decreases over time when these compounds are chronically
administered.

Steroidogenesis in the ovary and adrenal gland of the UI-

or FSH-injected rats was consistently less than comparable control values.
It was postulated that

PGF2~

and aspirin, a specific prostaglandin an-

tagonist, exert their effects at different levels of hormone action; i.e.
at the pituitary level, or at the ovarian or adrenal gland level, to
produce generalized steroidogenesis in the rat.
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INI'RODUCTION
In recent years, prostaglandin compounds have attracted much
research interest in their role as the second messenger system in hormone action.

Their intimate relationships with various reproductive

parameters is well documented.

One current problem which is being in-

vestigated, and reported herein, is the primary site of prostaglandin
action.

Several investigators have been trying to determine if prosta-

glandins exert their modifying action at the. pituitary level or at the
level of an end organ.

Recent studies, using the pituitary-ovarian

axis, and using prostaglandin compounds and their antagonists, have
indicated that prostaglandins may exert their effects at both the ovarian
and pituitary level (Orczyk and Behrman, 1972; Kuehl, Humes, Tarnoff,
Cirillo and Ham, 1970).
It should be pointed out that much of the research to date on prostaglandins and their relationships with reproductive function has been accomplished in in vitro systems.

,!!:. ~experimentation with prostaglan-

dins has been limited to the short-term effects of prostaglandins.

This

situation has been partly due to expense and limited availability of
prostaglandin compounds.

Only recently have prostaglandin compounds been

synthetically produced (Bagali, 1970; Pike, 1970).

Also,

in~

systems and short-term in vivo experiments allow a rigid control of
variables, thus increasing the validity of observed results.

Research

with prostaglandins is relatively new and such rigid experimental systems
1

2

have clearly established their importance in the biochemistry of a living
system.

Unfortunately, the aforementioned studies do not allow observa-

tions of the "dynamics" of prostaglandins.

The true effects of any com-

pound on the body is the sum total of its interactions with all other compounds, and in the end, must be evaluated from this standpoint in order
to ascertain its true significance.

For example, Horton and Marley (1969)

found that long-term administration of PGE 1 increased fertility in mice
as measured by litter size.

Such a study illustrates the effect of a

compound from the standpoint of total body interaction.
Another area of prostaglandin research which has been neglected is
the response of the sexually immature animal to prostaglandin compounds.
To date, most work has been accomplished on their effects in the mature
or gravid female, owing chiefly to the fact that prostaglandin compounds
have great potential in the area of fertility control, and as relatively
safe and effective abortifacient compounds (Duncan and Pharriss, 1970).
A series of experiments was designed to investigate the effects of
Prostaglandin F2o<

(PGF2o<) on the sexually immature rat ovary and adrenal

gland when given over a period of weeks during the critical stage of
sexual maturation.

Also, the effects of acetylsalicylic acid (aspirin),

a specific prostaglandin antagonist, was studied.

In addition, by con-

currently dosing other rats with luteinizing hormone (LR) and follicle
stimulating hormone (FSH), the similarities and differences of PGF 2 o< and

3

aspirin response as opposed to gonadotropin response on inunature rats was
compared.

End-points for comparison were gravimetric data of the ovary

and adrenal gland, and histologic morphology.and enzyme histochemistry
(dehydroepiandrosterone-3p-hydroxysteroid dehydrogenase) data on the
ovary.

REvmw OF THE LrrERATURE
A group of biologically active compounds, known as prostaglandins,
were first alluded to in 1913 when Battez and Boulet found that extracts
of human prostate had strong depressor action on blood pressure when injected into the dog.
ognized.

The true significance of their findings was not rec-

Lacking sophisticated techniques for isolation and characteriza-

tion of biological compounds, this was not considered a startling finding.
Extracts of just about any organ would elicit the same response due to
the ubiquitous occurrence of su.ch compounds as acetylcholine and histamine.
In 1930, two New York gynecologists, Kurzrok and Lieb, reported the
actions of human seminal fluid on isolated human uterine muscle strips.
They observed that seminal fluid produced both relaxation and contraction
of uterine smooth muscle, and that this action was in some way correlated
with past histories of pregnancy or sterility.

This particular study is

considered to be the first indication of differentiated, biologically
active compounds in semen.

Unfortunately, these actions were again at-

tributed to acetylcholine, and no further

work was done to characterize

the active principle.
Approximately four years later, two independent researchers co-discovered the existence of biologically active substances in seminal fluid
that were pharmacologically different from known compounds previously
described.

Goldblatt (1933), from England, described a depressor sub-

4
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stance in seminal fluid, but unfortunately reported his discovery, as a
brief abstract, in the journal Chemistry
biologists of that time.

~

Industry, little read by

Without knowledge of Goldblatt's work, von Euler

in Sweden, in 1934, reported essentially the same findings as Goldblatt,
working with human seminal fluid.

Subsequently, Goldblatt (1935) continued

his studies and described a variety of actions of seminal fluid, including
the finding that seminal fluid sensitized the seminal vesicle of the guinea
pig to adrenaline.

This

was a new, but as yet,

furth~red

the belief that the active principle

un~haracterized,

biological compound.

Dr. von Euler in 1935, with the help of Hugo T. Theorell, a chemist
at the Karolinska Institute, used electrophoresis to separate the different
fractions of seminal fluid and was able to characterize the active principle
as an acidic lipid.

Since the compound occurred in extracts of the prostate

and seminal vesicles, and was a new and previously unknown chemical, the
name prostaglandin was coined by von Euler.

To quote Professor von Euler,

"The ether and water soluble substance, which has the effects of lowering
blood pressure and stimulating various isolated smooth muscle organs, is
provisionally named prostaglandin" (von Euler, 1935).
Shortly after publishing his second paper in 1935, Dr. Goldblatt died.
Thus, all research on prostaglandins, for the next decade, was conducted in
von Euler's laboratory at the Karolinska Institute.

Dr. von Euler, in 1936,

was able to show that the acidic lipid was hydroxylated, and in 1939, concluded that the active principle was a lipid soluble, fatty acid that
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probably contained a double bond and a hydroxyl group.
Unfortunately, the Second World War halted any serious attempts at
further elucidating the chemistry and physiology of prostaglandin,

After

the war, von Euler was preoccupied with his recent discovery of norepinephrine and passed on his work to Dr. Bergstrom, a physician in biochemistry
at the Karolinska Institute.

Dr. Bergstrom, in 1949, reported that further

purification and characterization of sheep vesicular gland extracts showed
that, indeed, the active principle was composed of unsaturated hydroxy acids.
It was another seven years before any further work on prostaglandin,
then considered a single chemical entity, was attempted.

This circumstance

was primarily the result of inadequate technology in the early 1960 1 s
needed to isolate and identify minute amounts of unstable compounds.
Another factor was that the intestinal smooth muscle test used to assay
their activity was so unspecific that many scientific people did not
believe that prostaglandins were a new class of biologically active compounds.
In 1956, an intensive investigation, led by Dr. Bergstrom, was initiated.

Frozen sheep vesicular glands were collected in Iceland, Greenland

and Norway.

Eventually, enough active compound was extracted to obtain

prostaglandin factor in pure crystalline form.
was termed PGF.

This 'Prostaglandin Factor'

Bergstrom and Sjovall (1957), his co-worker, also reported

that at least one other active acidic factor was present in the extracts
of sheep vesicular glands.

7

In the next few years, further investigation by Bergstrom and his coworkers (1962), using new isotopic, mass spectrometric, and chromatographic
techniques, finally resulted in the isolation and elucidation of the structures of three of the primary prostaglandins, today known as Prostaglandin
E, Prostaglandin F2o< and Prostaglandin

F 2 ~.

But even at this point, fur-

ther biological testing was at a disadvantage since prostaglandin compounds
could not be produced efficiently in adequate quantities.

Finally, in

1964-65, investigators at Karolinska Institute, Sweden, Unilever Research
Laboratories in the Netherlands, and at the Up John Company in Kalamazoo,
Michigan, (U.S.A.), independently discovered how to synthesize prosta-.
glandins enzymatically by incubating essential fatty acid precursors with
sheep vesicular glands (von Dorp, Beerthuis, Nugteren and vonkeman, 1964;
Bagali, 1970; Bergstrom, Ryhage, Samuelsson and Sjovall, 1964).

Finally,

total synthesis of prostaglandins and their analogues was accomplished
(Bagali, 1970; Pike, 1970).
To highlight a few of the recent advances in prostaglandin research,
one of the most startling findings is the ubiquitous occurrence of these
compounds.

Although first isolated from seminal fluid and extracts of

male accessory sex glands, physiologic amounts have been recognized in
female sex organs, lung tissue, iris, the central and peripheral nervous
system, liver, pancreas, intestine, skeletal muscle and kidney (von Euler
and Eliasson, 1967).

In fact, they are probably found in physiologic

8

amounts in numerous tissues of the body.

It has recently been recognized

that prostaglandins are not strictly a manunalian compound.

Prostaglandins

have been identified in the skin and spinal cord of the frog, and more surprising, in living coral from the sea •.
Mysterious substances isolated in the past have recently been identified
as prostaglandins.

For example, "irin", first reported by Dr. N. Ambache

w.

Vogt as being a biologic-

ally active substance produced in the intestines;

Dr. V.R. Pickles' (1957)

in 1957; "darmstoff", described in 1949 by Dr.

"menstrual stimulant", which is reseased by the endometrium during menstruation; and "medullin", isolated from rabbit kidney in 1965 by Dr. James
Lee, have all been recognized as prostaglandins (von Euler and Eliasson,
1967).

There is recent evidence that a prostaglandin may be the "long-

searched-for" mediator of the inflammatory response (Donovan and Traczyk,
1962).
The biggest reason for the "explosion" of prostaglandin research
and interest in these chemicals by scientists in universities, clinics
and in pharmaceutical companies around the world is their potential
therapeutic usage.

Already the medical uses of prostaglandins include

induction of labor, therapeutic abortion, contraception, treatment of
dysmenorrhea, male sterility, prevention and therapy of peptic ulcer
and thrombosis, control of hypertension, bronchodilation in asthma and
nasal congestion.

Another broad field of investigation in pharmaceutical

companies is prostaglandin antagonists which may have widespread medical

9

usage.

At the 1970 New York Academy of Sciences Conference on Prostaglan-

dins, a paper on SC-19220, a dilienzo-x-azepine hydrazide derivative, a specific inhibitor of PGF2o< was presented by Sanner (published in 1971).
possible therapeutic uses of prostaglandin inhibitors include inflammation,
premature labor and dysmenorrhea.
At the present time, there are 14 naturally occurring prostaglandin
compounds, 13 of which have been found in man.

Prostaglandins are abbrevi-

ated as PG and naming of the different PG's is based on a hypothetical
molecule, prostanoic acid.
9
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Prostanoic Acid
From the above structure, the chemical nature of prostaglandins are
c-20 fatty acids containing a cyclopentane ring (Bergstrom, Ryhage, Samuelsson and Sjovall, 1962).

The different structures of the cyclopentane ring

subdivide the prostaglandins into four major groups: PGE, PGF, PGA and PGB.
The degree of unsaturation of the alkyl and carboxylic side. chains is
denoted by a subscript numeral after the group designation.

i"hus, subscript

1 denotes a double bond between C-13, 14; subscript 2 denotes two double
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bonds between C-13, 14 and C-5, 6; and subscript 3 indicates three double
bonds which include the two already mentioned and a third in the C-17, 18
position.
A further classification using subscript alpha or beta denotes the
stereo position of substituents on the cyclopentane ring.

If substituents

are on the same side of the ring as the carboxyl group, they are in the
alpha position; and those on the same side as the alkyl group are in the
beta position (Anderson, 1971).
The biosynthesis of the natural prostaglandins involves the precursors
c-20 essential fatty acids.

These essential fatty acids undergo cyclization

and introduction of molecular oxygen in the enzyme microsomal fractions of
the cell.

The primary precursors are Eicosartrinoic Acid (linolenic acid),

Eicosatetraenoic Acid (arachidonic acid) and Eicosapentaenoic acid (Bergstrom, Carlson and Weeks, 1968).

These three precursor fatty acids form

the six primary prostaglandin compounds (PG.El, PGE2, PGE3, PGFl<X' PGF2o(,
and

PGF 3 o{)~

groups.

Thus, all the primary prostaglandins are in the PGE and PGF

All six are designated as primary because none are a precursor

of the others.

By a series of enzymatic steps the other known naturally

occurring prostaglandins (PGA.1, PGA.2, PGB1, PGB2, and their 19-hydroxy
analogues) are derived from the six primary prostaglandins (Spero££ and
Rarnwell, 1970),
The mechanisms of action of the prostaglandins is, at this point, a
matter of controversy.

Pharmacologically, the prostaglandins mimic actions
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of hormones and neuro-hormones, modify hormonal actions, or inhibit the
hormonal actions depending on the tissue and specific prostaglandin
studied.

It is known that the PG's are biologically active in extremely

small amounts.

Dosage is measured in nanograms of prostaglandin per gram

tissue.
The theory which is backed up by the most scientific data is that
prostaglandins exert their effect by either inhibiting or increasing the
rate of cyclic AMP metabolism intracellularly.

It is also thought that

hormones have this same mechanism of action of exerting their effect
through cyclic AMP and adenyl cyclase systems; but prostaglandins, unlike
the hormone concept, display an extraordinary lack of tissue specificity
and modify cyclic AMP levels in many tissues (Butcher and Baird, 1968).
Recent evidence suggests that prostaglandins probably mediate their action
on cyclic AMP formation by modifying calcium levels within the cell (Shio,
Shaw and Ramwell, 1971).
The need for an intact cell membrane for PG effects to be exerted,
and the fact that prostaglandins bind to plasma proteins and cell membranes
in a manner analagous to that of free fatty acids, suggest that possibly
the site of action is in the plasma membrane itself (Shio, Shaw and Ramwell,
1971).

Another avenue of prostaglandin research in the area of action

mechanisms is the effects of prostaglandins in modifying cyclic AMP
control of RNA, and possibly DNA.

Previous evidence shows that exogenous

cyclic AMP modifies RNA and protein synthesis (Postan and Perlman, 1970).

12
The implication toward cancer research is obvious.
The mechanism of prostaglandin release is another area which is
receiving considerable interest.

Studies have shown that manunalian cells

apparently will secrete prostaglandin with a variety of mild, to severe,
but non-specific stimuli.

Examples include release of PGE 1 into splenic

venous blood of the dog when the splenic nerve was stimulated (Davis,
Horton and Withrington, 1968);

PGE 2 and PGF2 o< release in lung tissues

during anaphylaxis in guinea pigs (piper and Vane, 1969);

release of

PG's by the mere infusion of colloidal suspensions into the dog isolated
spleen (Gilmore, vane .and Wyllie, 1969).

One important feature of prosta-

glandin release has definitely been established: the sequence is prostaglandin biosynthesis followed by release, rather than prostaglandin storage
followed by release.

Lungs, adrenal glands, stomach, intestine and spleen

have all been shown to release more prostaglandin when stimulated than
they contained (Ramwell .and Shaw, 1970).

The theory relating to the

specific mechanisms of prostaglandin release which is favored today was
first advanced by Bennett in 1967, who proposed that PG release, in
general, was associated with distortion or activation of cell membranes
(Bennett, Friedman and vane, 1967).
Piper and Vane (1971) have worked extensively on this problem and have
forwarded two possibilities which suggest the local hormonal action of
prostaglandins and their function as a basic "defense mechanism" of the
body.

The first theory examines prostaglandin release as a function of
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the cellular need to resist change.

The example of smooth muscle stretching

correlated with an active increase in tension is given.

They feel this

physiological response is mediated by local prostaglandin release which
prevents over-distention and rupture or distortion of muscle fibers.
Another example related to the fact that PGE 2 inhibits noradrenaline
release in the spleen, and that PGE 2 is released in the spleen following
splenic contraction mediated via nerve stimulation with noradrenaline
release.

Thus, a negative feedback mechanism exists whereby the muscle

tissue can reduce a stimulus that causes its contraction.

Both examples,

·according to Piper and vane, 1971, show that prostaglandins can both
reduce the stimulus and minimize the potential injury.

The other theory

suggests that prostaglandin release facilitates tissue adaptation to disturbing stimuli.

For example, smooth muscle storage organs, such as the

bladder and stomach, will stretch without an increase in the muscle cell
tension.

Prostaglandins have a relaxing effect on these tissues.
Prostaglandin Action and the Ovary

The highest concentration and greatest number of different prostaglandins have been found in human seminal fluid.

Indeed, the discovery

of prostaglandins now known to be seemingly ubiquitous in the body were
first isolated and identified in human seminal fluid.

Since that time,

pharmacologically active prostaglandins have been demonstrated in menstrual
fluid, umbilical cord, amniotic fluid, decidua, proliferative and secretory

14
(progravid) endometrium, semen and vesicular glands (Speroff and Ramwell,
1970).

Since they occur in all reproductive tissues, and were first dis-

covered in secretions of the male reproductive tract, most investigation
of prostaglandins has been in conjunction with their role in reproductive
physiology.
Research on prostaglandin and the ovary have centered around three
central theses.

One is the role of prostaglandin in promoting luteolysis.

Another area of research concerns the relationships, if any, between cyclic
AMP, gonadotropin and prostaglandins.

Finally, steroidogenesis of different

hormones and prostaglandins has been investigated.
It has been known for several years that hysterectomy in different
pseudo-pregnant laboratory species will result in a prolonged life-span
of the corpus luteum.

Thus, it was speculated that a substance, luteolysin,

was produced in the uterus and caused this luteolytic effect.

Current

research into the problem has resulted in three candidates for "luteolysin",
PGF2o< , PGF1o<., and PGE 1 , which have been found to cause irreversible destruction of luteal tissue,

in~'

in the guinea pig (Blatchley and

Donovan, 1969; Gutknecht, Cornette and Pharriss, 1970), rabbit, rat and
hamster (Gutknecht, Pharriss and Wyngarden, 1971), and rhesus monkey
(Kirton, Pharriss and Forbes, 1970).
Pharriss, of Alza Corporation in Palo Alto, California, has summarized
his and other's investigations of this problem (Pharriss, 1971).

He sum-

marizes five theories of possible mechanisms of PGF 2o( in luteolysis: 1)
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direct feedback on the pituitary gland; 2) "anti-gonadotropic" effect; 3)
stimulation of uterus to produce luteolysin; 4) direct toxicity on the
corpus luteum; and 5) constriction of the utero-ovarian vein.

The most

plausible mechanisms seem to be gonadotropin antagonism and restriction
of ovarian blood flow.

It is known that PGF 2o(, injected DJ, will reduce

utero-ovarian venous blood flow without affecting flow in the kidney
(Pharriss, 1971).

It is further speculated that, although the mechanism

of luteolysis is, as yet, unclear, it is known that prostaglandins cause
pregnancy termination in laboratory animals, and that this is probably a
result of luteolysis.
Investigation into steroidogenesis of ovarian hormones and prostaglandins has resulted in conflicting information in light of the !!!_ vivo
luteolytic role of PGFzo( •

Several scientists have shown that in vitro

incubation of luteal slices with PGFz« causes a stimulation of progesterone synthesis (Pharriss, Wyngarden and Gutknecht, 1968; Speroff and
Ramwell, 1970).

It may be that

in~

luteolytic characteristics of PG's

exert a chronic action on local hemodynamics while
cellular changes.

~ ~

PG's exert

It is known that steroidogenesis is promoted in the

adrenal gland perfused with PGE 1 , PGEz, PGF 1oe, (Flock, Jessup and Ramwell,
1969).

Also, urinary cortisol levels are increased when PGF

2

~

is ad-

ministered intravenously in man (Wentz, Jones and Bledsoe, 1973).
The mechanism of prostaglandin mediation of cyclic AMP, and the relationship between cyclic AMP and hormonal actions has been previously
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described.

This cyclic AMP-prostaglandin relationship may very well be

the underlying mechanism in all observed prostaglandin actions involving
the ovary.

It has been shown that the effect of LH on steroidogenesis is

mediated via cyclic AMP (Marsh, 1968).

Recent papers on prostaglandins

and the ovary have established a relationship between luteolysis and
ovulation and PGF

2

o(

in the utero-ovarian blood of guinea pigs pre-treated

with estrogen (Blatchley, Donovan, Poyser, Horton, Thompson and Los, 1971).
Prostaglandin interaction and interrelationships with gonadotropins
has also proven to be a fruitful area of investigation.
these investigations is the work by Pharriss (1971).
in vivo experiments showed that PGF

2

Q(

~effects

Using immature rats,

inhibited the effects of PMS and

HCG by decreasing ovarian weight, and ovulation.
studying the in

Significant in

Labhsetwar (1971) in

of PGF 2 c:i( in the adult female rat found a

luteolytic activity but could not pinpoint the location of primary prostaglandin activity

<i·~·'

central or local).

Horton and Marley (1969), using

mice as the experimental animal, found that long-term administration of
PGE 1 increased fertility as measured by litter size.
Orczyk and Behrman (1972) found that administration of the prostaglandin antagonists, aspirin and indomethacin, blocked ovulation in the rat and
postulated that prostaglandins play a functional role in regulating the
release of LH necessary for ovulation in the rat.
Cirillo and Ham (1970), using the prostaglandin

Luehl, Humes, Tarnoff,

ant~gonist

prostynoic

acid, and PGF2v.; and LH, postulated that prostaglandin compounds exert

r
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their effect at both the pituitary and ovarian level.

A study by Behrman,

orczyk and Greep (1972) determined that the effects of aspirin and indomethacin, both antagonists of prostaglandin compounds, accomplish their biopharmacologic effects at different levels of hormone action.

Aspirin

blockage of ovulation was reversed by LH administration, but the ovulation
blockage by indomethacin could not be reversed by either LH or gonadotropin
releasing hormone.
It should be emphasized that very little work has been accomplished
on the effect of prostaglandins, or their antagonists, on the reproductive
maturation of an inunature animal..

In view of this, experimentation was

instituted to observe the effects of PGF2

°'

and acetylsalicylic acid, a

prostaglandin antagonist, on the immature rat ovary.and adrenal gland when
given over a prolonged period of time.

MA.TERIAI.S AND METHODS
I.

Animals Fnd Housing
A total of 190 innnature (21 day old), Sprague-Dawley derived female

rats (Locke-Erickson Laboratories, Inc., Maywood, Illinois) were separated
into nineteen experimental groups.

Rats were housed five to. a unit in

clear plastic "shoe-box" type caging on San-i-cel bedding (Paxton Laboratories, Paxton, Illinois).
Feed and water were given
.diet (Purina Lab Chow).

caging was cleaned and sterilized once weekly.
~

libitum.

Feed was a standard laboratory rat

They were all housed in the same room which was

environmentally controlled, i.e. temperature: 72° F. +two degrees, constant humidity 53%
II.

± 5%,

12 hour light-dark cycle.

Treatment categories
Five different treatment categories were defined in this experiment

on the basis of the type of drug or hormone given.

All drugs or hormones

were delivered subcutaneously using a 1.00 cc tuberculin syringe and a 26
gauge needle.

All drugs and hormones were given twice daily (BID), one

injection at 8.a.m. and the other at 4 p.m.
A.

Controls.

Two major groups of controls were designated.

group of controls was injected with 0.25 cc of 10% ethanol.

One

This group

was necessary to establish any variable that may be introduced using alcohol as a delivery vehicle for acetylsalicylic acid in another test group.
Another control group was not injected with any substance and was compared
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to the alcohol controls and other treatment groups.

One subgroup of 10

non-injected controls was necropsied at 22 days in order to establish
base-line values.

Subgroups of ten rats from the non-injected control

group and ten rats from the alcohol-injected control group were necropsied on days 27, 33 and 37, giving a total of 70 rats ..
B.
rats.

The prostaglandin group was divided into three subgroups of ten
All were injected with 0.075 mg of PGF2o< twice daily (0.075 cc)

from day 22 through the day prior to necropsy.
necropsied on days 27, 33 and 37, respectively.

The three subgroups were
The prostaglandin compound

was delivered frozen at a concentration of 10 mg/ml in phosphate buffer
(G.D. Searle Company, Skokie, Illinois).

This was diluted down to a con-

centration of 0.1 mg/ml with phosphate buffer solution at a pH of 7; and
then divided into 1.0 cc aliquots and frozen at -60° C. until use (Karim,
Devlin and Hillier, 1968).

Previous work by Labhsetwar (1972) has estab-

lished that 75 micrograms BID, given subcutaneously is a physiologic dose
in the rat.

c.

A total of thirty rats was assigned to this group.

Another treatment group was given acetylsalicylic acid (aspirin)

which was put into solution with 10% ethanol and injected at a dosage of
5.0 mg twice daily (0.25 ml, BID).

This dosage level is active in the

rat (Behrman, Qrczyk and Greep, 1972).

As in the prostaglandin group,

three subgroups of ten rats each were necropsied on days 27, 33 and 37,
respectively, and received injections of aspirin from day 22 until the
day necropsied, thus giving a total of thirty rats.
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D. 'The LR (Luteinizing Hormone) (Schwarz-Mann, Orangeburg, New York)
injected rats were given 0.125 Armour Unit

(LH-ovine, Armour 277-80, equiva-

lent to N.I.H. LH S-1) (Riddle, Bates and Dykshorn, 1933) of LH twice
daily from day 22 until the day of necropsy.

Three subgroups of ten rats

were sacrificed on days 27, 33 and 37, respectively, for a total of thirty
rats in this major treatment category.

The LH was received lyophilized

and was reconstituted with physiologic saline to deliver a dose in 0.05
cc.
E.

The FSH (Follicle Stimulating Hormone) (Schwarz-Mann, Orangeburg,

New York) was also received lyophilized and reconstituted with physiologic
saline and injected at a dosage of 0.25 Armour Standard Unit

(FSH-porcine,

Armour 264-151X, equivalent to 0.5 N.I.H. FSH S-1) (Steelman and Pohley,
1953) twice daily (0.05 cc, BID).

In this treatment category, also, three

subgroups of ten rats were necropsied on days 27, 33 and 37
of thirty rats), and were on a treatment schedule identical

(i·~·

a total

to the LR

group.
The age of the experimental rats (21 to 37 days of age) was chosen as
an appropriate interval to study the effects of these compounds on the
immature female rat during the period of vaginal canalization and the
development of reproductive competence (K.asprow, 1969).
III.

General Procedures
After completion of the different dosage regimes, all rats were
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necropsied after recording body weight to the nearest gram on a direct
reading torsion balance and euthanizing by ether anesthesia followed by
decapitation.

The ovary and adrenal glands were dissected free from

adhering fat and other tissue and weighed to the nearest 0.2 mg on a
Roller-Smith type torsion balance.

After weighing, the ovaries and

adrenals were either fixed in neutral formalin for histological study
or quick frozen in liquid nitrogen and stored at -600
analysis.

c.

for histochemical

In each subgroup of ten animals, the ovaries and adrenal glands

of five rats were formalin-fixed; the ovaries and adrenal glands from
the other five rats were frozen.
The formalin-fixed adrenal glands and ovaries were then washed,
dehydrated in alcohol, cleared with xylene and embedded in paraffin.

The

adrenal glands and ovaries were cut at six microns and stained with Harris
hematoxylin and eosin for histological examination.

Photomicrographs

were taken using Polaroid type 107 film and a Wild microscope.

Both

40X and lOOX magnification photomicrographs were made of each ovary for
comparison purposes.
The ovaries that were frozen were sectioned at eight microns and in-

Mdehydro(10-4) M

cubated for 3~ hours in a media containing 1.0 ml of 2.0 (10-4)
epiandrosterone (DHA), 1.0 ml propylene glycol, 1.0 ml of 5.0

nicotinamide-adenine dinucleotide (NAD) and 1.0 ml of 1.6 (10- 4 ) M nitro
blue tetrazolium chloride (Nitro-BT), all in 4.0 ml of phosphate buffer
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solution (pH-7.4).

A set of companion ovarian sections were incubated in

media without DHA and served as control groups.

Polaroid photomicrographs

of the incubated sections were used to measure semi-quantitative reactions.
This particular technique allows the localization and semi-quantification of
the enzyme dehydroepiandrosterone-3B-hydroxysteroid dehydrogenase (DHA-3pHSD), which is indicative of active estrogen biosynthesis (Kalvert and
Bloch, 1968).

The reaction was rated on a scale of 0 to +3, depending on

the degree of monoformazan or diformazan precipitate deposited on ovarian
tissu~

sections.

Plate I illustrates the semi-quantitate scale used.

EXPERIMENTAL RESULTS
A.

Control Female Rats
In an effort to provide some rigid base-lines for rigid comparisons,

a number of controls were studied in extenso, thus providing highly standardized bases for comparison,

i·~·,

controls at 22, 27, 33 and 37 days of

age, cf. Tables I and V, and accompanying photomicrographic documentation.
Body weights, ovarian weights and adrenal gland weights of the noninjected controls and the alcohol-injected (vehicle for aspirin) controls
were essentially identical (Tables I-IV).

Adrenal gland weights, when com-

pared on a milligrams per 100 grams body weight basis, showed a marked linear decrease from day 22 to day 33, of approximately 40% (from 20.5 mg% to
12.7 mg%),* and then plateaued (Table I and Text Figure 2).

This weight

decrease of adrenal glands in immature rats, before vaginal opening is consistent with the findings of Kasprow (1969).
Semi-quantitative histochemical estimates of average dehydroepiandrosterone-3~-hydroxysteroid

dehydrogenase (DHA-3p-HSD) activity in ovarian

sections of the non-injected control groups revealed little DHA-3¥-HSD activity in the 27 and 33 day old groups.

DHA-3p-HSD activity in the 37 day

old non-injected controls was significantly greater (approximately 33%
greater) and more variable (+2.00

± O. 71),

'J(*

than the 27 day old and 33 day

*
All organ weights are expressed in milligrams per 100 grams body
weight (mg%), unless otherwise indicated.
**

Average and standard deviation from the mean. Represents average of
estimates derived from the follicular, luteal and interstitial components
of the ovaries.
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TABLE I
GRAVIMETRIC DATA ON THE BODY, OVARJES AND ADRENAL GIANDS OF THE NON- INJECTED CONrROL GROUPS OF
22, 27, 33 AND 37 DAYS OF AGE
Age in Days
22

--

27

33

37

!l(ll)

10

10

9

10

Item
g, mg(b)
range
'%(d)
mg o
range
g, mg
range
mg%
range
g, mg
range
mg%
range
g, mg
range

b
c
d

-

Adrena-1 Gland Weight
8.5
5.5-11.6

37,6 + 4.3
28.6-42.2
22.7
16.8-30.6

20.5 + 4.9
14 8-26.6
-----·9.4
8.3-13.1

92 + 6.4
84-l02

38.2 + 5.1
32 .2-47 .8
26.0
20.9-33.6

15. 7 + 1. 9
13.4-18.5
11.8
8.0-15.3

123+12.3
111-149

28.2 + 5.0
22.7-38.0
35.1
23.5-57.2

12. 7 + 2 .4
8.7-15.2
16.3
11. 7-23.0

28.3 + 7.0
19.8-40.9

13.3 + 1.9
9.9-15.o

59 + 7. 5
51-73

mg%
range
a

Ova ria ~ Weight
15.4
10.3-18.9

Body Weight
41 .± 5.3(c)
36-51

.

Number of rats in group.
Body weights expressed in grams, organ weights are combined weights of both ovaries/adrenal
glands expressed in milligrams. Data represents average values
Standard deviation from the arithmetic mean.
Organ weights expressed in milligrams per 100 grams body weight.

N

~
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old subgroups (41..50

± 0.55

and-tl.40

± 0.55,

respectively; cf. Table V,

Text Figure 3 and Plate II, figures 5 and 6).

It should be noted that

values of DHA-3B-HSD
activity represent averages of estimates or enzyme
I
activity derived from the follicular, luteal and interstitial tissue components of the ovaries (Kovarik, 1972).
B.

Prostaglandin F2 o< -Injected Female Rats.
Body weights and ovarian weights of the Prostaglandin F2 c< -injected

rats showed no significant variation from the weights of the 27, 33 and 37
day old non-injected controls.

Average ovarian weights, on a mg% basis,

were 37.3 at 27 days, 29.9 at 33 days and 26.0 at 37 days (Tables II-IV and
Text Figure 1).

Adrenal gland weights were significantly greater than

control values in the 27 and 33 day subgroups (P = <0.01 and <0.10, respectively;*** cf. Tables II-IV and Text Figure 2).

In the 27 day old

PGF2 ol subgroup, there was an approximate 33% increase in average weight
of the adrenal glands over control values.

The average weight of, the

adrenal glands at 27 days of age was 19.0 mg% in the PGF 2o( -injected rats
compared to 15.7 mg% average adrenal gland weight in the 27 day old noninjected control rats.

At 37 days of age, the average adrenal gland

weight when compared to controls was not significantly different (P

=

<0.20).
Average DHA-3p-HSD, as estimated semi-quantitatively in ovarian sections, revealed elevations and patterns similar to the changes in average
*** P = probability of differences when compared to the non-injected
control values ("student's" t-distribution).

TABLE II
GENERALIZED AND SUMMARIZED GRAVIMETRIC DATA ON THE BODY, OVARIES AND ADRENAL GIANDS OF THE
27 DAY OID TREATMENf GROUP

Treatment
I.

Alcohol
(0.2S cc of 10%
ethanol, BID)

n (a) Item

Bodl Wei~ht

Ovarian

10

60+7.6(c)
so -:: 71

22.4
17.1-31.0

9.4
7.0-12.9

37.5 ±S.O_
31.1 - 46 .3

15. 7_:t2.0,
13.2 - 18.6

20. 7
16. 9 - 28.7

10.S
9.2 - 14.3

37 .2 + 4.4
16. 9 -:: 2 8. 7

19.0 + 1.1
16.4 -:: 20. 7
<0.001

g' mg(b)
range
mg%(d)
ran~e

p(e

II.

Pros tag land in F 2 oc
(7S micrograms,
BID)

10

g, mg
range
mg%
range
p

SS + S.S
49 -:: 69

Wei~ht

<0.20

Adrenal Gland

Wei~ht

\.

III.

Aspirin
(S.O milligrams,
BID)

8

.g, mg
range
mg%
range
p

S4 + 4. s
47 -:: 62

< 0.20

20.9
16.2 - 24.0

10.0
8.7 - 12. 3

38.9 + 4.8
29.S -:: 4S.6

18. 9 + 2. 7
lS.S-:: 22.4
<0.01

- Contuned N

°'

.

TABLE II (continued)
Treatment
IV.

v.

n

10
Follicle Stimulating Hormone
(0.025 Armour Unit,
BID)

Luteinizing Hormone 10
(0.125 Armour Stan<lard Unit, BID)

Item

Body Weight

Ovarian Weight

Adrenal Gland Weight

g, mg
range

68 + 8.1
56 -:: 84

26. 9
20.9 - 41. 7

7.8 - 11.4

39.0 + 8.6
30.8-:: 57.9

mg %
range
p

<0.02

g, mg
range

65 + 3.6
60 -:: 71

mg%
range
p

<0.01

9.4
13 .8 + 1.8
11. 1 -:: 16. 0

<0.05
32.0
16.5 - 41.8

8.0 - 11.3

9.6

48.8 + 11.2
2 7. 5 -:: 64. 3

14.8 + 1. 9
11.3 - 16.9

<0.02

aNumber of rats in group.
bBody weights expressed in grams, organ weights are combined weights of both ovaries/adrenal
glands expressed in milligrams. Data represents average values.
cStandard deviation from the arthmetic mean.
d

Organ weights expressed in milligrams per 100 grams body weight.

eProbability of differences of average body weights in grams or average ovarian/adrenal gland
weights in mg% when compared to non-injected control values ("student's t-distribution). Probabilities
of <0.20 or less reported.
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weights of adrenal glands in the
(Table V).

PGF 2 ~

subgroups at comparable days of age

There was high DHA-3p-HSD activity at day 27 (P=<0.05) and at

day 33 (P=<0.10) when compared to control values; but at day 37, enzyme
activity was similar to control values (Table V and Plate III, Figures 7
and 8).

± 0.55

Average semi-quantitative estimates of enzyme activity were +2.40
at 27 days of age, +2.20 + 0.80 at 33 days of age and +1.75

at 37 days of age for the

PGF ~

2

± 0.49

subgroups.

MorphOlogic examination of histologic sections. revealed corpus luteal
formation at day 37 in the

PGF ~

2

treatment category.

This finding is in-

consistent with the short-term effects of PGF 2o( administration,
will cause irreversible destruction of luteal tissue !.!!,

~

i·~·'

PGF 2o(

(Blatchley and

Donovan, 1969).

c.

Aspirin-Injected Female Rats.
There was a

marke~

similarity between the effects of acetylsalicylic

acid (aspirin) a.nd PGF2 o( on the ovarian weights, adrenal gland weights and
average DHA-3p-HSD activity in the ovaries.

Adrenal gland weights were in-

creased significantly at day 27 over control averages (P=<O. 01).

Average

adrenal gland weight was 18.9 mg% in the 27 day aspirin subgroup compared
to 15.7 mg% in the 27 day non-injected control subgroup (Tables I and II,
and Text Figure 2).

At days 33 and 37, adrenal gland weights were compar-

able to those of the controls.

Average adrenal gland weight was 13.9 mg%

at both 33 and 37 days of age in the aspirin-injected rats, compared to

TABLE III
GENERALIZED AND SUMMARIZED GRAVIMETRIC DATA ON THE BODY, OVARIES AND ADRENAL GLANDS OF THE
33 DAY OLD TREATMENT GROUP

Treatment
I.

II.

Alcohol
(0.25 cc of 10%
ethanol, BID)

Prostaglandin F2
(75 micrograms
BID)

n(a)

Item

Body Weight

Ovarian Weight

Adrenal Gland Weight

10

g, mg(b)
range

93 + 7 .4(c)
80 :- 105

26.2
19.3 - 33.1

8.2 - 15.1

28.5 + 6.3
20.8 -:: 41.4

12. 5 + 2 .2
8.8 --15.6

26.5
19.5

13.2
9.8 - 19.6

29.9 + 8.8
22.1-:: 49.l

14. 7 + 1. 9
12.6-:: 18.0

mg%(d)
range
p(e)
o<

10

g, mg
range

90' + 11.2

76-103

mg%
range
p

III.

Aspirin
( 5. 0 milligrams

7

g, mg

range

11.6

<0.10

89 + 12.7
63-98

25.6
20.3 - 45.0

12.4
10.6 - 17 .4

28.4 + 6.4
20.4 :- 40.2

13.9 + 1. 5

BID)

mg%
range
p

- Continued -

11.8 :- 15.5

TABLE III (contined)

Treatment
IV.

n

Item

Body Weight

Ovarian Weight

Adrenal Gland Weight

10

g, mg
range

103 + 12.2
89 - -125

39.9
29.4 - 50.6

12.5
9.9 - 18.9
12 .1 + 1.3
9. 9 - -14.1

p

<0.05

38.4 + 5.5
32._0 - 46.6
<0.001

g, mg
range

101 + 16.2
64 --117

44.1
29.4 - 55.6

13.2
10.5 - 15.3
13.3 +2.5
9.5-18.3

<0.20

43.8 + 6.2
36 . 4 ::- 54 . 5
< .001

Follie le Stimulating Hormone
(0. 02 5 Armour
Unit, BID)

mg %

range

v.

Luteinizing Hormone
(0.125 Armour Standard Unit, BID)

9

mg%
range
p

8

Number of rats in group.

bBody weights expressed in grams, organ weights are combined weights of both ovaries/adrenal
glands expressed in milligrams. Data represents average values.
cStandard deviation from the arthmetic mean.
dOrgan weights expressed in milligrams per 100 grams body weight.
eProbability of differences of average body weights in grams or average ovarian/adrenal gland
weights in mg% when compared to non-injected control values (''student's "t-distribution). Probabilities
of <0.20 or less reported.
w
0
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12.7 mg% at 33 days and 13.3 mg% at 37 days for the controls (Tables I-IV
and Text Figure 2).

At 37 days of age, ovarian weight was not increased

significantly over control values, 30.9 mg% compared to 28.3 mg% for controls.

Interestingly enough, all rats were cycling at this period, and

such variations in ovarian weights can be expected normally, as previously
shown earlier by Kasprow (1969).
Average DHA-3p-HSD activity in the ovaries of the aspirin treated rats
increased markedly and significantly (approximately a 67% increase, P=<0.025)
at day 33 when compared to controls, but was unchanged from control values
at days 27 and 37.
activity was +l.50

Average semi-quantitative estimates of DHA-3p-HSD

± 0.58

at 27 days, +2.50

37 days for the aspirin treated rats.

± 0.91

at 33 days and +2.00 at

Comparable control values were +l.50

+ 0.58 at 27 days, +1.40 + 0.55 at 33 days and +2.00

± 0,71

(Table V and Plate IV, Figures 9 and 10, and Text Figure 3).

at 37 days
Histologic

sections of the ovaries of the aspirin treatment group revealed luteal
formation at 27 days of age, while no control ovaries showed corpus luteum
formation until 37 days.
In the 37 day old aspirin subgroup, gross body weight was significantly
less (P=<0.05) than comparable control body weights.

Average body weight

of the 37 day control rats was 123 grams, while the 37 day aspirin-injected
subgroup had an average body weight of 110 grams (Tables I and IV).
salicylate intoxication could account for this weight difference.

Chronic

TABLE IV
GENERALIZED AND SUMMARIZED GRAVIMETRIC DATA ON THE BODY, OVARIES AND ADRENAL GIANDS OF THE
37 DAY OID TREATMENf GROUP

Treatment

I.

II.

Alcohol
(0.25 cc of 10%
ethanol BID)

n(a)

Item

Bodi Weight

Ovarian Weight

Adrenal Gland Weight

10

g, mg(b)
range

122 + 13.9(~)
109 :- 155

35.8
23.3 - 61.0

15.8
12.0 - 21.4

28.9 + 71.
20.0 :- 39.4

13.0 + 1.9
10.3 :- 15.9

30.1
21.0 - 44.4

15.4
12.3 - 21.4

26.0 + 7.2
18.1 :- 37.5

12. 9 + 1. 7
10.1:: 15.4

34.2
20.0 - 47.8

15.2
11.8 - 17.3

30.9 + 7.6
19.6 :- 39.5

13. 9 + o. 8
12. 7 :- 14. 9

Pros tag landin F 2 co( 9
(75 micrograms
BID)

mg%(d)
range
p(e)

<0.01

g, mg
range

120 + 15.6
88 - -139

mg%
range
p

III.

Aspirin
(5. 0 milligrams

8

g, mg
range

110 + 12 .1
85 - -122

BID)

mg%
range
p.,

<0.05
- Continued I,..)

N

TABLE J!.l (Continued)

Treatment
J!.l.

Follicle Stimulating Hormone
(0.025 Armour
Unit, BID)

n

Item

Body Weight

Ovarian Weight

Adrenal Gland Weight

10

g, mg
range

127 + 8.1
115 :- 142

43.1
28.6 - 52.4

16.9
12.7 - 22.8

34.0 + 6.8
24.0 :- 43.1
<0.10

13 .2 + 1. 7
11. 0 :- 16 .1

48.4
32.3 - 63.0

16.1
13.7 - 20.6

38 .4 + 6 .1
29. 3 :- 48. 1
<0.005

12 .9 + 1.8
10. 5 :- 16. 0

mg%

range
p

V.

Luteinizing Hormone 10
(0.125 Armour Standard Unit, BID)

g, mg

range

126 + 9.3
110 :- 144

mg%

range
p

aNumber of rats in group.
bBody weights expressed in grams, organ weights are combined weights of both ovaries/adrenal
glands expressed in milligrams. Data represents average values.
cStandard deviation from the arthmetic mean.
dorgan weights expressed in milligrams per 100 grams body weight.
eProbability of differences of average body weights in grams or average ovarian/adrenal gland
weights in mg% when compared to non-injected control values ("student's" t-distribution). Probabilities of <0.20 or less reported.
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D.

Follicle Stimulating Hormone-Injected and Luteinizing Hormone-Injected
Female Rats.
Follicle Stimulating Hormone (FSH) at the dose levels used in this

experiment caused a significant increase in average body weights of the
27 day old (P=<0.02) and 33 day old (P=<0.05) FSH rats when compared to
those of the controls.

Body weight averages were 68 grams compared to 59

grams, and 103 grams compared to 92 grams for controls, respectively
(Tables I-III).

The 37 day old FSH subgroup was also heavier than controls

(127 grams vs. 123 grams for controls), but the difference was not statistically significant.

Luteinizing Hormone (LR) also caused significant

body weight increases in the 27 day old LR subgroup (P=<0.01).

Average

body weight was 65 grams compared to 59 grams for the 27 day control subgroup (Tables I and II).

Body weight increases in the 33 and 37 day LR

subgroups was also recorded, but was not significantly changed from control
values.

Average body weight for the 33 and 37 day LH subgroups was 101 and

126 grams respectively (Tables III and IV).

An explanation of these weight

increases in both the FSH and LR groups could be possible contamination of
the gonadotropin preparations with Growth Hormone (GH).
The adrenal glands of the FSH and LR groups showed weight decreases
when compared to control values at 27, 33 and 37 days of age.

The weight

of the adrenal glands of the 27 day FSH subgroup was significantly less
(P=<0.05) than average control values.

The average adrenal gland weights

of the 27, 33 and 37 day FSH subgroups were 13.8 mg%, 12.1 mg% and 13.2 mg%,

TABLE V
GENERALIZED AND SUMMARIZED DATA BASED ON THE SEMI-QUANTITATIVE HISTOCHEMICAL ESTIMATES OF AVERAGE
DEHYDROEPIANDROSTERONE-3~-HYDROXYSTEROID DEHYDROGENASE (DHA-3j3-HSD) ACTIVITY IN OVARIAN SECTIONS
OF THE CONTROL AND TREATMENT GROUPS

8 Number

of rats in group.

bAverage and standard deviation from the mean. Represents average of estimates of DHA-3 -HSD
activity derived from the follicular, luteal and interstitial components of the ovaries.
Cprobability of differences when compared to the non-injected controls ("student's" t-distribution).
Only probabilities of <0.20 or less reported.
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respectively, 14.8 mg%, 13.3 mg% and 12.9 mg% for the I1i subgroups, respectively, and for the non-injected control subgroups, 15.7 mg%, 12.7 mg% and
13.3 mg%, respectively (Tables I-IV and Text Figure 2).
Ristologic sections of the ovaries of the FSR group revealed multiple
follicular development with early luteinization when compared to control
sections.

Also

in this experiment, the FSR group showed statistically

significant increases in average ovarian weights in the 33 day old subgroup
(P=<0.001).

Average control weight for the 33 day ovarian weights was 28.2

mg%; while comparable FSR ovarian weight average was 38.4 mg%.

The 27 day
f.·~·

and 37 day average ovarian weights were comparable to control values,

39.0 JI€;% vs 38.2 mg% for control ovaries at 27 days, and 34.0 mg% vs 28.3

'

---

.

mg% for the controls at 37 days, (Tables I-IV and Text Figure 1).

---

Velardo

(1958) reported that FSR, when given subcutaneously in inunature rats,
resulted in ovarian weight increases and luteinization when given over a
period of days.
Ovarian weights were greatly increased in the LR group when compared
to the non-injected control animals.

The average ovarian weights of the

LR subgroups was of a greater magnitude than comparable FSH values.

This

weight increase was significant, when compared to controls, in the 27(P=<0.02), 33- (P=>0.001) and 37- (P=<0.005) day old LR subgroups.
Recorded ovarian weight averages were 48.8 mg%, 43.8 mg% and 38.4 mg%,
respectively (Tables I-IV and Text Figure 1).

Also, histologic sections
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of the ovaries in the LH group revealed luteinization at day 27, much
earlier than comparable control sections which did not reveal luteinization
until day 37.

Pure IH preparations will cause formation of corpora lutea

in inunature female rates if prior growth of graafian follicles is stimulated
by FSH (Greep, van Dyke and Chow, 1942).
Average DHA-3p-HSD activity was decreased when compared to control
values at 27, 33 and 37 days of age for both the IH and FSH subgroups.
This decrease was significant (P=<0.05) in the 37 day LH subgroup..

The

average semi-quantitative estimates of enzyme activity were +1.20

± 0.45,

+1.20

± 0.45

and +1.40

± 0.55

respectively, and were +1.40

for the 27-, 33- and 37-day old FSH subgroups,

± 0.55,

+l.50

± 0.58

and +1.20

27-, 33- and 37-day old IH subgroups, respectively.

± 0.45

for the

very little diformazan

deposits were observed in any ovarian sections from either the FSH or LR
groups.

Most ovarian sections in both the FSH and LH groups showed only

monoformazan deposits (Table V, Text Figure 3 and Plate V, Figures 11 and
12).

TEXI FIGURE

i

GRAPH SHOWING GRAVIMETRIC DATA ON THE OVARIES OF IMMATURE FEMALE RATS WHEN EXPOSED TO THE DIFFERENT
TREATMENT REGIMES INDICATED (DATA BASED ON COMBINED WEIGHTS OF BOTH OVARIES CONVERTED INTO MILLIGRAMS
PER 100 GRAMS BODY WEIGHT, i.e. MG%)
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DISCUSSION
It is postulated that prostaglandins exert their effects by regulating
intracellular levels of adenosine 3 1 , 5 1 -monophosphate (cyclic AMP).

Cyclic

AMP is considered to be the second messenger of hormone action (Sutherland
and Rall, 1960; Shaw and Ramwell, 1968).

Studies with prostaglandins and

their effect on hormone action have revealed that prostaglandins (PG's)
can serve in both a positive and a negative feedback role in hormone
action (Steinberg, Vaughan, Nestel, Strang and Bergstrom, 1964).

The

prostaglandins, as a group, will mimic actions of hormones and neurohormones, modify hormonal actions, or inhibit the hormonal actions depending on the tissue and specific prostaglandin studied,

~

Y.!.Y£.

studies

compared with in vitro actions of the same prostaglandin compound sometimes
reveal conflicting end results.

In vitro incubation of luteal slices with

PGFzo(cause a stimulation of progesterone synthesis (Pharriss, Wyngarden and
Gutknecht, 1968), while Labhsetwar (1971) found that
adult female rat causes irreversible luteolysis.
prostaglandin synthesis

in~

(Vane, 1971).

in~

PGFzo( in the

Aspirin will inhibit
Prostaglandins will increase

steroidogenesis in in vitro preparations of rat adrenal glands (Flock,
Jessup and Ramwell, 1969) and salicylates in the !,!l vivo system will also
cause an increase in adrenal steroidogenesis (Done, Ely and Kelly, 1958).
It appears that there are several pronounced contradictions insofar
as the biological actions of the prostaglandins are concerned.

One explana-

tion for these apparent contradictions is the importance of recognizing
41

42

different levels of prostaglandin action.
~varian

In the case of

f.!!.

~

PGF o(
2

steroidogenesis, a cellular phenomena is a possible explanation

while the

~

vivo luteolytic activity of PGF 2 o{ may represent a chronic

action on local hemodynamics of the ovary (Pharriss, 1971).

Aspirin in-

creases ACTH levels in the body which results in adrenal steroidogenesis
(Done, Ely and Kelly, 1958).

Thus, aspirin may exert its effect at the

pituitary level by pituitary stimulation of ACTH release while PGF 2 CI( may
exert its effect at the adrenal level to cause steroidogenesis, resulting
in the identical end result of increased steroidogenesis.
In an effort to ascertain some critical lines of data on the biological
actions of the prostaglandins, several experiments were undertaken.

First,

a series of controls were thoroughly assessed, so as to provide rigid
baselines on comparisons.

Secondly, a four part experimental procedure was

undertaken: (a) Rats of 22 days of age were given 0.075 milligrams of PGF2o<
twice daily (B]J)) and necropsied at 27, 33 and 37 days of age;

(b)

5.0

milligrams of aspirin B]J) were similarly given, and the rats were necropsied
according to the aforementioned schedule; (c) Likewise, 0.025 Armour Unit
of FSH were similarly studied; and finally (d) LH (0.125 Armour Standard
Unit) was assessed as per the experimental schedule.

Two distinctive

parameters were pursued: (1) the gravimetrics of the endocrine organs,
with specific notes on reproductive events, and (2) the changing nature of
DHA-3p-HSD co-incident with maturity and treatment with each of the substances named,

~·a·

PGF2o( , aspirin, FSH and UI.
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In this study, DHA.-3~-HSD activity in the ovary was used as an indication of specific steroidogenesis in the ovary.

DHA-3p-HSD is required

for biosynthesis of estradiol 17-p and estrone in the ovaries of rats
(Kalvert and Bloch, 1968).

Adrenal gland weights (on a mg% basis) were

used as supportive of metabolic activity in this endocrine organ.

Injected

ACTH will cause steroidogenesis in the rat adrenal with a concomitant
increase in weight; hypophysectomy will cause a decrease in steroidogenesis
and, also, a decrease in adrenal weight (Kitchell and Wells, 1952).

In

Cushing's syndrome in man, there is hypercortisolism and enlarged, hyperplastic adrenal glands (Anderson and Cleveland, 1969).

The ovarian weight

is not a good indication of steroidogenesis in the ovary since ovarian
weight is more dependent on morphologic components

present,!·~·'

follicles,

corpora lutea (Kasprow, 1969).
This thesis reports similar end-results of increased estrogen synthesis
in the ovary, and increased adrenal weights in immature female rats, when
given either PGF2o{ or aspirin over a period of weeks.

Possibly aspirin is

working at the pituitary level and PGF 2 o( , when given systemically, works
at the end organ level to produce a generalized steroidogenic effect in the
body with either compound.

Another possible explanation is that aspirin

only effects PG synthetase and not formed prostaglandins.
apparent

.!:!!. vitro

In view of the

antagonism of aspirin and PGF2o( , it is interesting to

note their similarity in promoting increased steroidogenesis in the ovary
and adrenal glands in the i:!!,

~

system.

Also in comparing the actions
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of the PGFzo( and aspirin, after approximately two weeks of chronic administration, their effects on steroidogenesis in the adrenal gland and ovary
is insignificant when compared to the non-injected controls.
~ ~

system adapts to these high levels of

PGF ~

2

a drug insensitivity or tolerance phenomenon occurs.

Perhaps the

and aspirin, or perhaps
This apparent insensi-

tivity is also illustrated in the 37 day PGF2 o( group which showed luteal
tissue in histologic sections of the ovary.

Short-term~~

PGF

2

o(

administration in the adult female rat causes irreversible luteolysis (Labhsetwar, 1971).

Another explanation could be deterioration of the PGFzo(

and aspirin solutions, and, thus, loss of biologic activity over time.
Also, one should consider the fact that dose remained constant over time
while body weight increased markedly over this time period of rapid growth,
thus effectively decreasing dose per unit weight levels.
Vogt (1957) and Kasprow (1969), using bilaterally ovariectomized rats
injected with estradiol

17-~,

reported uterine weight increases and signifi-

cant increases in adrenal weights.

In this study, increases in estradiol-

17p synthesis in the ovary, as measured by DHA-3¥-HSD activity in the
ovary, resulted in comcomitant increases in adrenal weights.

Perliaps the

same mechanism is operating in both instances to increase adrenal steroidogenesis.

Estradiol-17p synthesis could

directly influence adrenal steroido-

genesis by providing the chemical precursors for adrenal steroid hormones

45
(Hechter, Solomon, Zaffaroni and Pincus, 1953).

Another possibility is an

estradiol-17p feedback mechanism on the pituitary to influence tropic hormone release (Vogt, 1957).
Investigations utilizing prostaglandins and prostaglandin inhibitors
(aspirin, indomethacin and prostynoic acid) and comparing their modifying
action on gonadotropin response have indicated that the level of prostaglandin action is an important variable when considering prostaglandin
action in the in

~

system..

Orczyk and Behrman (1971) reported that both

aspirin and indomethacin will block ovulation in the rat.
domethacin reduced PGF
mus

2

PGF ~

o(

2

concentrations.

Aspirin and in-

plasma concentrations and pituitary and hypothalaUtilizing gonadotropic releasing hormone and LR

to reverse the effects of ovulation blockage in the rat with aspirin and
indomethacin, the site of ovulation blockage of these drugs was elucidated
(Behrman, Orczyk and Greep, 1972).

It was determined that aspirin blocked

ovulation at the pituitary level, while indomethacin probably exerted its
effect at the ovarian level.

LR reversed aspirin ovulation blockage, but

not indomethacin ovulation blockage.

Thus, prostaglandins probably act at

both the pituitary and ovarian levels to influence hormonal actions on the
ovary.
Evidence also suggests prostaglandin interaction at the level of the
hypothalamus.

PGE

1

will stimulate ACTH release when placed in the rat

hypothalamus, but has no effect when placed directly in the pituitary of
the rat (Hedge, 1971).
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The exact relationship between prostaglandins, gonadotropins and cyclic
AMP, is another area of current investigation.

Prostaglandin E1 and LH will

cause cyclic AMP production when incubated with mouse ovary; this effect is
blocked with the addition of prostynoic acid, a specific prostaglandin inhibitor (Kruehl, Humes, Tarnoff, Cirillo and Ham, 1970).

Grinwick, Kennedy

and Armstrong (1972) reported a dissociation of ovulatory and steroidogenic
properties of LH by studying indomethacin effects on rabbit ovaries.
methacin blocked ovulation but did not prevent luteinization.

Indo-

Such studies

indicate possible multiple interactions between gonadotropins and prostaglandins at the cellular level.

It should be emphasized that there are

many conflicting reports of prostaglandin action in the literature.

Much

work must be accomplished to establish the valid role of prostaglandingonadotropin interactions.
Another interesting observation was the decrease in growth rates
of the

a~pirin-treated

rats.

This observation could simply reflect the

generalized toxic effects of salicylates but also could indicate interference or antagonism of various pituitary hormones which influence growth.
Vaginal opening was also delayed; but early luteinization of the ovary was
observed in the aspirin group.
Also in this study, there was a consistent decrease in DHA-3p-HSD
activity in the ovarian sections of the LR and FSH groups.

Ovarian histo-

morphology revealed early luteinization when compared to control ovarian
sections.

FSH, when given without LH, causes follicular development, but
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without LH, estrogen synthesis is minimal (Turner, 1971).

Histologic

sections of the ovaries in the FSH group revealed multiple follicular development with early luteinization.

Velardo (1958) reported that FSH, when

given subcutaneously in immature rats resulted in ovarian weight increases
and luteinization when given over a period of days.

Fevold (1941) indicated

that relatively pure preparations of FSH are inefficient in inducing biosynthesis of estrogen in the immature rat ovary.

Lack of estrogen synthesis

was apparent in this study by the lack of DHA-3p-HSD activity in the ovary.
Fevold (1941) also reported that LH, when given alone, does not stimulate
estrogen synthesis.

Both LH and FSH, in the proper ratio, are necessary to

stimulate estrogen biosynthesis (Velardo, 1958 and 1960).
Also of note in this study was a consistent decrease in adrenal gland
weight of the FSH and LH group when compared to control values.

Earlier

in this discussion it was noted that estradiol-17p will cause adrenal gland
weight increases when injected subcutaneously in rats (Kasprow, 1969).

DHA-

3p-HSD activity in the ovaries of the rat is indicative of estradiol-17p
synthesis (Kalvert and Bloch, 1968).
previously noted that

DHA-3~-HSD

control DHA-3p-HSD activity.

In the LH and FSH subgroups, it was

activity was less, on the average, than

The decrease in estradiol-17p synthesis

could explain the decrease in adrenal gland weights in the LH and FSH groups.
Companion studies not reported in this dissertation did not show any
significant uterine weight increases within the aspirin or PGF2o( subgroups.
DHA-3p-HSD studies on these same ovaries did show significant increases
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in estrone and estradiol-17p synthesis.

Estradiol-17p· will cause significant

uterine weight increases at a dosage of 0.1 microgram (Kasprow, 1969).

3p-HSD activity in the ovary apparently is a more sensitive

DHA-

indicator of

estrogen synthesis than uterine weight changes in the rat.
Regarding the dynamic role of the prostaglandins in the body, much
remains for future study.

The literature is replete with contradictions

and vague generalities concerning these biologically active compounds.

Their

ubiquitous occurrence in many tissues of the mammalian body, and the possibility of species differences somewhat tend to confuse experimental
design and results.

Invest.igations into the area of endocrine physiology

of the reproductive tract and prostaglandin interaction have only resulted
in speculation of the roles of prostaglandin in reproductive functions.
It may very well be that prostaglandins are the long recognized,
but previously unknown, luteolytic agents, initiators of parturition and
agents responsible for ovum transport and sperm capacitation.
evidence for the latter exists.

Some such

Therapeutic applications of the PG's have

been surprizingly successful up to this point.

The intensity of research

in the area of prostaglandin biochemistry and physiology will undoubtedly
shed new light on their true significance in the mammalian body in the near
future.

SUMMA.RY AND CONCLUSIONS
1.

A series of experiments were undertaken to observe the effects of

prostaglandin F2 o( (PG1" 2 o(), acetylsalicylic acid (aspirin), follicle stimulating hormone (FSH) and luteinizing hormone (LH) on estrogen biosynthesis
in the ovary as revealed histochemically; also pursued were the histologic
morphology of the ovary, and the gravimetric changes of the ovaries, adrenal
glands and body weights of immature, female rats when given the aforementioned drugs during the period of developing reproductive competency.
Five major groups of thirty 22 day old female rats (one control group
and four treatment groups) were given subcutaneous injections, twice daily,
of either 75 micrograms of PG1"2o( , give milligrams of aspirin, O. 25 Armour
Unit

of FSH or 0.125 Armour Standard Unit

of LH.

Sub-groups of ten rats

in each major treatment category were necropsied at 27, 33 or 37 days of
age.

Body weights, ovarian weights and adrenal gland weights were recorded

and statistically analyzed.

Ovarian sections were prepared for histologic

morphology, and for histochemical analysis,

i·~·'

dehydroepiandrosterone-

3p-hydroxysteroid dehydrogenase (DHA-3¥-HSD) activity, which is indicative
of the precursors of estrone and estradiol-17p biosynthesis in the ovary.
DHA-3p-HSD activity in the ovary, and adrenal gland weights were used as
indices of the metabolic activity in these endocrine organs.
2.

Both PGF 2o( and aspirin significantly increased (at the 0.05 level

of predictability or less) the dehydroepiandrosterone-3p-hydroxysteroid
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dehydrogenase (DHA-3p-HSD) activity in the ovary over comparable control
values in the 27 and 33 day PGF o{ subgroups and the 33 day aspirin sub2
group.

Activities of DHA-3p-HSD in the LR- and FSH-injected rats were

consistently below control levels throughout the experimental procedures.
DHA-3p-HSD ovarian activity in the PGF2o( and aspirin injected rats approached control values after 16 days of continuous injections of these compounds.

Average semi-quantitative ovarian DHA-3p-HSD activities on a

to "+3" scale were: +1.50

± 0.58,

+1.40

± 0.55

and +2.00

± 0.71

± 0.80

an:l +1.75

± 0.49

0 11

for the 27,

33 and 37 day old non-injected control subgroups, respectively; +2.40
+2.20

11

± 0.55,

for the 27, 33 and 37 day old PGF 2oc -injected

subgroups, respectively; +l.50

± 0.58,

+2.50 + 0.91 and +2.00 + 0.82 for

the 27, 33 and 37 day old aspirin-injected subgroups, respectively; +1.20

-+ 0.45,

-

+1.20 + 0.45, and +1.40 + 0.55 for the 27, 33 and 37 day old FSH-

-

injected subgroups, respectively; and +1.40

± 0.45
3.

± 0.55,

+l.50

+ 0.58 and +1.20

for the 27, 33 and 37 day old LR-injected subgroups, respectively.
Ovarian weights were not significantly different, when compared

to controls, for the PGF 2 o( and aspirin treatment groups.

The FSH and LR

groups showed statistically significant ovarian weight increases throughout
the experimental procedure.

Statistically significant average ovarian

weight increases were recorded in the 33 day old FSH subgroup, and in the
27, 33 and 37 day old LR subgroups.
Recorded average ovarian weights, on a milligrams per 100 grams body
weight (mg%) basis were: 38.2, 28.2 and 28.3 for the 27, 33 and 37 day old
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non-injected control subgroups, respectively

37.3, 29.9 and 26.0 for the

27, 33 and 37 day old PGF o(-injected control subgroups, respectively; 38.9,
2
28.4 and 30.9 for the 27, 33 and 37 day old alcohol-injected (vehicle for
aspirin) subgroups, respectively; 39.0. 38.4 and 34.0 for the 27, 33 and
37 day old FSR-injected subgroups, respectively; and 48.8, 43.8 and 38.4
for the 27, 33 and 37 day old LR-injected subgroups, respectively.
4.

Ristomorphologic comparisons of ovarian sections revealed early

luteinization in the LR, FSR and aspirin groups, but the ovaries of the
PGF2 0( -injected rats resembled control sections,
5.

Adrenal gland weights in the PGF2 o( and aspirin treatment groups

were significantly increased over control values in the 27 and 33 day old
PGF2 o{ subgroups, and in the 27 day old aspirin subgroups.

This increase

in average adrenal gland weights over control values paralleled DHA-3p-RSD
activity in the ovary for

th~

PGF

2

o(

and aspirin groups.

Again, as with

DHA-3p-RSD activity, adrenal weights were comparable to control values
after 16 days of continuous injections of either PGF 2 o( or aspirin.

FSR-

and IJI-injected rats showed consistent decreases of adrenal weight, but this
decrease was not statistically significant, when compared to controls.
Average adrenal gland weights, on a mg% basis, were 15.7, 12.7 and
13.3 for the 27, 33 and 37 day old non-injected controls, respectively;
19.0, 14.7 and 12.9 for the 27, 33 and 37 day old PGF2 o( -injected subgroups,
respectively; 18.9, 13.9 and 13.9 for the 27, 33 and 37 day old aspirininjected subgroups, respectively; 13.9, 12.1 and 13.2 for the 27, 33 and 37

I
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day old FSR-injected subgroups, respectively; and 14.8, 13.3 and 12.9 for
the 27, 33 and 37 day old LR-injected subgroups, respectively.
6.

Body weights in the FSR and LR groups were consistently and sig-

nificantly increased over body weights of comparable control groups.

It

was postulated that possible growth hormone contamination of the LR and FSR
preparations could account for this weight increase.

Aspirin-injected rats

showed a significant decrease in body weight at 37 days when compared to
controls.

It was postulated that this weight decrease in the aspirin

group could reflect interference with pituitary hormones which influence
growth, or could simply reflect the generalized toxic effect of the salicylates.
Recorded average body weights in grams were: 59, 92 and 123 for the
27, 33 and 37 day old non-injected control subgroups, respectively; 55, 90
and 120 for the 27, 33 and 37 day old PGF 2 o(-injected subgroups, respectively;

54, 89 and 110 for the 27, 33 and 37 day old aspirin-injected sub-

groups, respectively; 68, 103 and 127 for the 27, 33 and 37 day old FSRinjected subgroups, respectively; and 65, 101 and 126 for the LR-injected
subgroups, respectively.
7.

It was concluded, from the aforementioned observations, that both

PGF 2 o( and aspirin, a specific prostaglandin antagonist, will increase
ovarian and adrenal steroidogenesis in the immature female rat; and that
this steroidogenic effect decreases over time when these compounds are
chronically administered.

It was postulated that aspirin and PGF o{
2
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may exert their effects at different levels of hormone action;
the pituitary level, or at the ovarian or adrenal level.

i·~·'

at
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Introductory Note to Plates
All photornicrographs are of cross sections of ovaries.

Photornicro-

graphs were taken using Polaroid type 107 film and a Wild microscope.
All photomicrographs are at lOOX magnification.
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PIATE I

Photomicrographs of sections of ovaries from rats which were incubated
with dehydroepiandrosterone (DHA) showing the semi-quantitative histochemical scale of DHA-3~-hydroxysteroid dehydrogenase (DHA-3~-HSD) activity
in ovarian sections.
Fig. 1.
Control section of ovary incubated without DHA.
a "0" reaction (lOOX).

Represents

Fig. 2.
Represents a "+l" reaction. Very little diformazan deposits
are in evidence, and DHA-3~-HSD activity is evidenced by rnonoformazan deposits (lOOX).
Fig. 3.
Represents a "+2" reaction. Discrete diformazan and monoformazan deposits are in evidence (lOOX).
Fig. 4.
Represents a "+3" reaction.
deposits are in evidence (lOOX).

Confluent areas of diformazan

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4
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Photomicrographs of sections of ovaries from the non-injected
contol rats which were incubated with dehydroepiandrosterone (DHA)
to localize the sites of estrogen biosynthesis,i·~·' DHA-3p-hydroxysteroid dehydrogenase (DHA-3~-HSD) activity.
Fig. 5.
Ovarian section from a 33 day old non-injected control rat
showing moderate (+2) DHA-3~-HSD activity in the interstitial
tissue and the theca interna of the tertiary follicles. The antrum
shows a typically negative reaction (lOOX).
Fig. 6.
Ovarian section from a 37 day old non-injected control rat
showing strong (+3) DHA-3~-HSD activity in the interstitial tissue
and in the theca interna of the follicles. Moderate (+2) DHA-3~
HSD activity is seen in the granulosa cells of the follicles (lOOX).
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Photomicrographs of sections of ovaries from the PGF2 ~ -injected
rats which were incubated with dehydroepiandrosterone (DHA) to localize
the sites of estrogen synthesis, i·~·' DHA-3p-hydroxysteroid dehydrogenase (DHA-3p-HSD) activity.
Fig. 7.
ovarian section from a 27 day old PGF 2 ~ -injected rat showing
moderate (+2) to strong (+3) DHA-3~-HSD activity in the interstitial
tissue and in the theca interna of the follicles (lOOX).
Fig. 8.
Ovarian section from a 37 day old PGF2 x -injected rat showing
moderate (+2) to strong (+3) DHA-3~-HSD activity in the interstitial tissue and weak (+l) to moderate (+2) DHA-3~-HSD activity
in the theca interna of the follicles (lOOX).
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FIGURE 7

FIGURE 8
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Photomicrographs of sections of ovaries from the aspirin-injected
rats which were incubated with dehydroepiandrosterone (DHA) to localize
the sites of estrogen synthesis, i·~·' DHA-3p-hydroxysteroid dehydrogenase
(DHA-3~-HSD) activity.
Fig. 9.
Ovarian section from a 27 day old aspirin-injected rat
showing weak (+l) DHA-3p-HSD activity in the interstitial tissue,
and in the theca interna and granulosa cells of the follicle.
Some diformazan deposits are in evidence in the interstitial
tissue (lOOX).
Fig. 10.
Ovarian section from a 33 day old aspirin-injected rat
which shows strong (+3) DHA-3~-HSD activity in the subcapsular
interstitial tissue and moderate (+2) DHA-3~-HSD activity in the
theca interna of the follicles (lOOX).
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Photomicrographs of sections of ovaries from the FSH- and lllinjected rats which were incubated with dehydroepiandrosterone (DHA)
to localize the sites of estrogen biosynthesis, i·~·' DHA-3B-hydroxysteroid dehydrogenase (DHA-3B-HSD) activity.
Fig. 11.
Ovarian section from a 37 day old FSH-injected rat showing
weak (+l) DHA-3p-HSD activity in the interstitial tissue, and in
the theca interna and granulosa cells of the follicles (lOOX).
Fig.· 12.
Ovarian section from a 37 day old Lll-injected rat showing
weak (+l) DHA-3p3-HSD activity in the corpus luteum, interstitial
tissue, and in ~he theca interna and granulosa cells of the
follicle (lOOX).
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FIGURE 11
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Fig. 13. ovarian section from a 37 day old non-injected control rat
cut at eight microns and stained with Harris hematoxylin and eosin.
Both follicular and corpus luteal structures are evident (lOOX).

FIGURE 13
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